For research use only. Not for therapeutic Use.
Avizakimab (BOS161721) is a humanized IgG1 monoclonal antibody that targets interleukin-21[1].
Avizakimab (BOS161721) prevents IL-21 binding to the IL-21 receptor (IL-21R) and inhibits bioactivity[1].
Avizakimab inhibits the downstream signaling, plasma cell differentiation, and natural killer cell activation induced by IL-21 and suppressed antibody responses to keyhole limpet hemocyanin (KLH) antigen[1].
| Catalog Number | I042168 |
| CAS Number | 2229685-51-0 |
| Purity | ≥95% |
| Reference | [1]. Hussaini A, et al. A Double-Blind, Phase I, Single Ascending Dose Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of BOS161721 in Healthy Subjects. Clin Transl Sci. 2020 Mar;13(2):337-344. |
